Lilly, Gilead lead pharma’s M&A boom

Lilly, Gilead lead pharma’s M&A boom is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-05-07

Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.

Source: PharmaVoice